BrainQ raises US$40 million for its stroke therapy home device

ISRAEL – Israeli stroke therapy technology startup BrainQ, has raised US$40 million to support a multicenter pivotal trial for its groundbreaking technology for ischemic stroke survivors in selected US hospitals. This funding round pioneered by Hanaco Ventures has brought total funds raised by the healthtech startup to over US450 million shillings. This year, BrainQ received FDA Breakthrough Device Designation allowing the company to work closely with the FDA to expedite development plans and premarket clearance, with access to the new Medicare Coverage of Innovative Technology pathway. “We’ve seen great advancements…

Read More

Somalia receives boost of US$20 million from USAID to combat COVID-19

SOMALIA – The United States Agency for International Development (USAID) has renewed its unwavering commitment to enhance the protection, health, and wellbeing of the most vulnerable children in Somalia by contributing an additional US$20 million to the United Nations Children’s Fund (UNICEF). These funds will play an integral role in supporting the organization and its partners to boost local capacity and reinforce the resilience of communities and systems in responding to the COVID-19 pandemic and other crises facing the country. So far, USAID has made donations totaling to US$ 34.7…

Read More

Uganda confirms Polio outbreak even after WHO’s wild-polio free certification

UGANDA – Ugandan Ministry of Health has declared Polio a Public Health Emergency in Uganda following confirmation of positive laboratory tests from environmental samples in Kampala. This comes after the World Health Organization (WHO), certified Uganda and the rest of Africa as wild-Polio virus free in August 2020. Samples collected from two sentinel environmental sites in Kampala and tested at Uganda Virus Research Institute (UVRI) confirmed a circulating Vaccine Derived Polio Virus type 2(cVDPV2). The virus detected has genetic linkage with a cVDPV2 strain reported in Sudan. Polio is a…

Read More

MHRA approves Moderna COVID-19 shot for 12 to 17-year-olds

UK – The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Moderna’s COVID-19 vaccine for use in children aged 12 to 17 years, weeks after the Pfizer shot was given a greenlight for deployment in this age set. The UK’s health regulator has confirmed the vaccine, known as Spikevax, is safe and effective in this age group, the statement read.  While most children develop mild or no symptoms with COVID-19, they are still able to spread the virus and some remain at risk of becoming seriously ill. Moderna’s vaccine…

Read More